Back

NASH: Pointers for Pharma from the Patient's Perspective

Read the article here.

The disease was first identified in the 1980s. Since then, its prevalence has grown rapidly in line with that of NAFLD, now one of the most common liver diseases worldwide. These trends reflect a growing epidemic of type 2 diabetes and obesity worldwide. One recent meta-analysis found the global prevalence of NAFLD to be around 25%, while the global prevalence of NASH is estimated at 3-5%.

Back

Our site uses cookies or similar technologies to recognise your repeated visits and preferences for us to deliver an optimal browsing experience. Please remember to read our privacy statement.

By clicking on "I Accept" or "X" to continue your browsing on this site, you consent to the use of the cookies. To find out how you can disable cookies on your device, please click here.

I Accept